| http://dbpedia.org/ontology/abstract
|
Methoxphenidine (methoxydiphenidine, 2-MeO … Methoxphenidine (methoxydiphenidine, 2-MeO-Diphenidine, MXP) is a dissociative of the diarylethylamine class that has been sold online as a designer drug. Methoxphenidine was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury. Shortly after the 2013 UK ban on arylcyclohexylamines methoxphenidine and the related compound diphenidine became available on the gray market, where it has been encountered as a powder and in tablet form. Though diphenidine possesses higher affinity for the NMDA receptor, anecdotal reports suggest methoxphenidine has greater oral potency. Of the three isomeric anisyl-substituents methoxphenidine has affinity for the NMDA receptor that is higher than 4-MeO-Diphenidine but lower than 3-MeO-Diphenidine, a structure–activity relationship shared by the arylcyclohexylamines.onship shared by the arylcyclohexylamines.
|
| http://dbpedia.org/ontology/casNumber
|
127529-46-8
|
| http://dbpedia.org/ontology/fdaUniiCode
|
H2W7A6GZGX
|
| http://dbpedia.org/ontology/pubchem
|
67833251
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Methoxphenidine_structure.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageID
|
41255861
|
| http://dbpedia.org/ontology/wikiPageLength
|
10107
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1099858799
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Phencyclidine +
, http://dbpedia.org/resource/AD-1211 +
, http://dbpedia.org/resource/Arylcyclohexylamine +
, http://dbpedia.org/resource/Lanicemine +
, http://dbpedia.org/resource/Category:Diarylethylamines +
, http://dbpedia.org/resource/Category:NMDA_receptor_antagonists +
, http://dbpedia.org/resource/NMDA_receptor +
, http://dbpedia.org/resource/Category:Dissociative_drugs +
, http://dbpedia.org/resource/Health_Canada +
, http://dbpedia.org/resource/NMDA_receptor_antagonist +
, http://dbpedia.org/resource/Category:Phenol_ethers +
, http://dbpedia.org/resource/Lefetamine +
, http://dbpedia.org/resource/Designer_drug +
, http://dbpedia.org/resource/Category:Designer_drugs +
, http://dbpedia.org/resource/MT-45 +
, http://dbpedia.org/resource/Lorazepam +
, http://dbpedia.org/resource/Category:Piperidines +
, http://dbpedia.org/resource/Structure%E2%80%93activity_relationship +
, http://dbpedia.org/resource/Dissociative_drug +
, http://dbpedia.org/resource/Diphenidine +
, http://dbpedia.org/resource/Ephenidine +
, http://dbpedia.org/resource/Driving_under_the_influence +
, http://dbpedia.org/resource/Fluorolintane +
, http://dbpedia.org/resource/Anisole +
|
| http://dbpedia.org/property/c
|
20
|
| http://dbpedia.org/property/casNumber
|
127529
|
| http://dbpedia.org/property/chemspiderid
|
52085156
|
| http://dbpedia.org/property/h
|
25
|
| http://dbpedia.org/property/iupacName
|
-1
|
| http://dbpedia.org/property/legalCa
|
Schedule I
|
| http://dbpedia.org/property/legalDe
|
NpSG
|
| http://dbpedia.org/property/legalStatus
|
Illegal in China and Sweden
|
| http://dbpedia.org/property/legalUk
|
PSA
|
| http://dbpedia.org/property/n
|
1
|
| http://dbpedia.org/property/o
|
1
|
| http://dbpedia.org/property/pubchem
|
67833251
|
| http://dbpedia.org/property/routesOfAdministration
|
Oral, Rectal
|
| http://dbpedia.org/property/smiles
|
COC1=CCN3CCCCC3
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
QXXCUXIRBHSITD-UHFFFAOYSA-N
|
| http://dbpedia.org/property/unii
|
H2W7A6GZGX
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Ionotropic_glutamate_receptor_modulators +
, http://dbpedia.org/resource/Template:Hallucinogens +
, http://dbpedia.org/resource/Template:Drugbox +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Phenol_ethers +
, http://dbpedia.org/resource/Category:Diarylethylamines +
, http://dbpedia.org/resource/Category:Designer_drugs +
, http://dbpedia.org/resource/Category:NMDA_receptor_antagonists +
, http://dbpedia.org/resource/Category:Dissociative_drugs +
, http://dbpedia.org/resource/Category:Piperidines +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Methoxphenidine?oldid=1099858799&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Methoxphenidine_structure.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Methoxphenidine +
|
| owl:sameAs |
http://rdf.freebase.com/ns/m.0zmx722 +
, http://dbpedia.org/resource/Methoxphenidine +
, http://www.wikidata.org/entity/Q15708281 +
, http://yago-knowledge.org/resource/Methoxphenidine +
, https://global.dbpedia.org/id/Yio6 +
, http://hr.dbpedia.org/resource/2-MeO-difenidin +
|
| rdf:type |
http://dbpedia.org/class/yago/WikicatNMDAReceptorAntagonists +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/class/yago/Organism100004475 +
, http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/class/yago/LivingThing100004258 +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/class/yago/Whole100003553 +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/CausalAgent100007347 +
, http://dbpedia.org/class/yago/Object100002684 +
, http://dbpedia.org/class/yago/Adversary109773245 +
, http://dbpedia.org/class/yago/Person100007846 +
, http://dbpedia.org/class/yago/YagoLegalActorGeo +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/class/yago/YagoLegalActor +
|
| rdfs:comment |
Methoxphenidine (methoxydiphenidine, 2-MeO … Methoxphenidine (methoxydiphenidine, 2-MeO-Diphenidine, MXP) is a dissociative of the diarylethylamine class that has been sold online as a designer drug. Methoxphenidine was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury. Shortly after the 2013 UK ban on arylcyclohexylamines methoxphenidine and the related compound diphenidine became available on the gray market, where it has been encountered as a powder and in tablet form. Though diphenidine possesses higher affinity for the NMDA receptor, anecdotal reports suggest methoxphenidine has greater oral potency. Of the three isomeric anisyl-substituents methoxphenidine has affinity for the NMDA receptor that is higher than 4-MeO-Diphenidine but lower than 3-MeO-Diphenidine, a structure–activity relatio-Diphenidine, a structure–activity relatio
|
| rdfs:label |
Methoxphenidine
|
